Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Mem Inst Oswaldo Cruz ; 109(3): 335-9, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24821058

RESUMEN

A non-controlled longitudinal study was conducted to evaluate the combined vaccine against measles, mumps and rubella (MMR) immunogenicity in 150 children vaccinated in the routine of three health units in the city of Rio de Janeiro, Brazil, 2008-2009, without other vaccines administered during the period from 30 days before to 30 days after vaccination. A previous study conducted in Brazil in 2007, in 1,769 children ranging from 12-15 months of age vaccinated against yellow fever and MMR simultaneously or at intervals of 30 days or more between doses, had shown low seroconversion for mumps regardless of the interval between administration of the two vaccines. The current study showed 89.5% (95% confidence interval: 83.3; 94.0) seroconversion rate for mumps. All children seroconverted for measles and rubella. After revaccination, high antibody titres and seroconversion rates were achieved against mumps. The results of this study and others suggest that two MMR doses confer optimal immunoresponses for all three antigens and the possible need for additional doses should be studied taking into account not only serological, but also epidemiological data, as there is no serological correlate of protection for mumps.


Asunto(s)
Anticuerpos Antivirales/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Paperas/inmunología , Seroconversión , Anticuerpos Antivirales/sangre , Brasil , Femenino , Humanos , Esquemas de Inmunización , Lactante , Estudios Longitudinales , Masculino , Sarampión/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Paperas/prevención & control , Rubéola (Sarampión Alemán)/inmunología
2.
Cad Saude Publica ; 31(1): 121-36, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25715297

RESUMEN

The aim of this study was to estimate the global burden of disease from external causes in 2008 in Brazil, based on DALYs (disability-adjusted life years). YLLs (years of life lost) were estimated according to the method proposed by Murray & Lopez (1996). Meanwhile, the method for estimating YLDs (years lived with disability) included methodological adjustments taking the Brazilian reality into account. The study showed a total of 195 DALYs per 100 thousand inhabitants, of which 19 DALYs were related to external causes. Among YLLs, 48% were from unintentional causes and 52% from intentional causes. Among YLDs, unintentional causes predominated, with 95%. The share of YLLs in DALYs was 90%. The cause with the highest proportion of YLLs was "homicide and violence" (43%), followed by "road traffic accidents" (31%). Falls accounted for the highest share of YLDs (36%). The sex ratio (male-to-female) was 4.8 for DALYs, and the predominant age bracket was 15-29 years. Since external causes are avoidable, the study provides potentially useful information for policymakers in public security and health.


Asunto(s)
Años de Vida Ajustados por Calidad de Vida , Heridas y Lesiones/mortalidad , Distribución por Edad , Factores de Edad , Brasil/epidemiología , Causas de Muerte , Costo de Enfermedad , Femenino , Sistemas de Información en Salud , Estado de Salud , Humanos , Esperanza de Vida , Masculino , Prevalencia , Factores Sexuales
3.
Cad Saude Publica ; 31(10): 2169-84, 2015 Oct.
Artículo en Portugués | MEDLINE | ID: mdl-26735384

RESUMEN

The objective of this study was to compare estimates of external causes based on the Global Burden of Disease in Brazil Study for the years 1998 and 2008. Methods included estimation of DALYs (disability-adjusted life years) and YLL (years of life lost), based on the methodology proposed in the Global Burden of Disease Study. Calculation of YLD (years lived with disability) required applying the same methodology in both years, with the 2008 methodology as the standard. Although external causes accounted for some 10% of total DALYs in both years, their internal distribution showed marked differences between regions of Brazil, with a decrease in the Southeast and increase in the North and Northeast. There was an increase in intentional causes, and YLLs accounted for the largest share of DALYs. The results can support new policies and/or improve existing ones to address external causes.


Asunto(s)
Causas de Muerte , Heridas y Lesiones/mortalidad , Adolescente , Adulto , Distribución por Edad , Brasil/epidemiología , Humanos , Esperanza de Vida , Masculino , Persona de Mediana Edad , Años de Vida Ajustados por Calidad de Vida , Factores Sexuales , Adulto Joven
4.
Contemp Clin Trials ; 41: 1-8, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25476584

RESUMEN

This study aimed to determine if immunogenicity to measles-mumps-rubella vaccine delivered to infants via a disposable-syringe jet injector (DSJI) was non-inferior to that administered by needle and syringe (NS). Vaccination safety was evaluated, as were the use, performance, and acceptability of each delivery method. The DSJI was the PharmaJet 2009 generation-1 device (G1) and the vaccine was measles-mumps-rubella vaccine from Bio-Manguinhos. Five hundred eighty-two healthy Brazilian infants were randomized to receive vaccine via G1 or NS. Seroconversion rates against measles and mumps viruses in the G1 treatment group did not meet non-inferiority criteria when compared with the NS group; however, responses in the G1 group to rubella virus were non-inferior to those of NS vaccinees. Most adverse events were mild or moderate. Crying after injection was more frequent in the NS group, and local skin reactions were more common in the G1 group. Five serious adverse events were judged causally unrelated to treatment and all resolved. Parents/guardians expressed a strong preference for G1 over NS for their children. Vaccinators found the G1 easy to use but noted incomplete vaccine delivery in some cases. Although the G1 has been superseded by an updated device, our results are important for the continued improvement and evaluation of DSJIs, which have the potential to overcome many of the challenges and risks associated with needle-based injections worldwide. Recommendations for future DSJI clinical studies include rigorous training of vaccinators, quantitative measurement of wetness on the skin following injection, and regular monitoring of device and vaccinator performance.


Asunto(s)
Inyecciones Subcutáneas/instrumentación , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Sarampión/prevención & control , Paperas/prevención & control , Rubéola (Sarampión Alemán)/prevención & control , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Brasil , Equipos Desechables , Femenino , Humanos , Inmunoglobulina G/inmunología , Lactante , Masculino , Sarampión/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/uso terapéutico , Paperas/inmunología , Aceptación de la Atención de Salud , Rubéola (Sarampión Alemán)/inmunología , Jeringas
5.
Vaccine ; 32(49): 6676-82, 2014 Nov 20.
Artículo en Inglés | MEDLINE | ID: mdl-24837504

RESUMEN

Neurological adverse events following administration of the 17DD substrain of yellow fever vaccine (YEL-AND) in the Brazilian population are described and analyzed. Based on information obtained from the National Immunization Program through passive surveillance or intensified passive surveillance, from 2007 to 2012, descriptive analysis, national and regional rates of YFV associated neurotropic, neurological autoimmune disease, and reporting rate ratios with their respective 95% confidence intervals were calculated for first time vaccinees stratified on age and year. Sixty-seven neurological cases were found, with the highest rate of neurological adverse events in the age group from 5 to 9 years (2.66 per 100,000 vaccine doses in Rio Grande do Sul state, and 0.83 per 100,000 doses in national analysis). Two cases had a combination of neurotropic and autoimmune features. This is the largest sample of YEL-AND already analyzed. Rates are similar to other recent studies, but on this study the age group from 5 to 9 years of age had the highest risk. As neurological adverse events have in general a good prognosis, they should not contraindicate the use of yellow fever vaccine in face of risk of infection by yellow fever virus.


Asunto(s)
Enfermedades del Sistema Nervioso Central/inducido químicamente , Vacuna contra la Fiebre Amarilla/administración & dosificación , Vacuna contra la Fiebre Amarilla/efectos adversos , Fiebre Amarilla/prevención & control , Adolescente , Adulto , Factores de Edad , Anciano , Brasil , Niño , Preescolar , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Adulto Joven
6.
Cad. saúde pública ; 31(10): 2169-2184, Out. 2015. tab, graf
Artículo en Portugués | LILACS | ID: lil-770594

RESUMEN

Resumo O objetivo foi comparar as estimativas das causas externas provenientes do estudo Carga Global de Doenças, entre os anos 1998 e 2008. A estimação do DALY (disability-adjusted life year) e do YLL (years of life lost) foi baseada em metodologia do estudo Carga Global de Doenças. Para o cálculo do YLD (years lived with disability), foram incluídas informações sobre atendimentos em emergências. Para comparabilidade, fez-se necessária a aplicação da mesma metodologia nos dois momentos analisados, tendo sido a mais recente eleita como padrão de referência. Em ambos os anos as causas externas foram responsáveis por cerca de 10% do total do DALY. Entretanto, sua distribuição interna apresentou marcada diferença entre as regiões do Brasil, com queda no Sudeste e aumento no Norte e Nordeste. Houve aumento das causas intencionais e o DALY se tornou mais letal (maior parcela de YLL). Espera-se que tais resultados balizem a formulação de políticas e/ou o aprimoramento das já existentes com vistas ao efetivo enfrentamento das causas externas.


Abstract The objective of this study was to compare estimates of external causes based on the Global Burden of Disease in Brazil Study for the years 1998 and 2008. Methods included estimation of DALYs (disability-adjusted life years) and YLL (years of life lost), based on the methodology proposed in the Global Burden of Disease Study. Calculation of YLD (years lived with disability) required applying the same methodology in both years, with the 2008 methodology as the standard. Although external causes accounted for some 10% of total DALYs in both years, their internal distribution showed marked differences between regions of Brazil, with a decrease in the Southeast and increase in the North and Northeast. There was an increase in intentional causes, and YLLs accounted for the largest share of DALYs. The results can support new policies and/or improve existing ones to address external causes.


Resumen El objetivo fue comparar las estimaciones de las causas externas desde el estudio Carga Global Enfermedades entre los años 1998/2008. La estimación de los DALY (disability-adjusted life year) e YLL (years of life lost) se basó en la metodología del estudio Carga Global de Enfermedades. Para el cálculo de YLD (years lived with disability), era necesario aplicar la misma metodología en ambos períodos, siendo elegido como el último punto de referencia. Pese a que en ambos períodos las causas externas fueron responsables de alrededor del 10% del total de DALY, su distribución interna mostró marcadas diferencias entre las regiones brasileñas con una caída en el Sudeste y un aumento en el Norte y Noreste. Se observó un aumento de causas intencionales y la YLL fue responsable de la mayor proporción de DALY en todos los grupos de causas externas. Se espera que estos resultados balicen la formulación de políticas y/o la mejora de las que ya existen, con el fin de hacer frente eficazmente a las causas externas.


Asunto(s)
Adolescente , Adulto , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Causas de Muerte , Heridas y Lesiones/mortalidad , Distribución por Edad , Brasil/epidemiología , Esperanza de Vida , Años de Vida Ajustados por Calidad de Vida , Factores Sexuales
7.
Mem. Inst. Oswaldo Cruz ; 109(3): 335-339, 06/2014. tab
Artículo en Inglés | LILACS | ID: lil-711723

RESUMEN

A non-controlled longitudinal study was conducted to evaluate the combined vaccine against measles, mumps and rubella (MMR) immunogenicity in 150 children vaccinated in the routine of three health units in the city of Rio de Janeiro, Brazil, 2008-2009, without other vaccines administered during the period from 30 days before to 30 days after vaccination. A previous study conducted in Brazil in 2007, in 1,769 children ranging from 12-15 months of age vaccinated against yellow fever and MMR simultaneously or at intervals of 30 days or more between doses, had shown low seroconversion for mumps regardless of the interval between administration of the two vaccines. The current study showed 89.5% (95% confidence interval: 83.3; 94.0) seroconversion rate for mumps. All children seroconverted for measles and rubella. After revaccination, high antibody titres and seroconversion rates were achieved against mumps. The results of this study and others suggest that two MMR doses confer optimal immunoresponses for all three antigens and the possible need for additional doses should be studied taking into account not only serological, but also epidemiological data, as there is no serological correlate of protection for mumps.


Asunto(s)
Femenino , Humanos , Lactante , Masculino , Anticuerpos Antivirales/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Paperas/inmunología , Seroconversión , Anticuerpos Antivirales/sangre , Brasil , Esquemas de Inmunización , Estudios Longitudinales , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Sarampión/inmunología , Paperas/prevención & control , Rubéola (Sarampión Alemán)/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA